Upexi (UPXI) Competitors

IN8bio (NASDAQ:INAB) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk.

Does the media favor INAB or UPXI?

In the previous week, IN8bio had 3 more articles in the media than Upexi. MarketBeat recorded 4 mentions for IN8bio and 1 mentions for Upexi. Upexi's average media sentiment score of 0.62 beat IN8bio's score of 0.26 indicating that Upexi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, INAB or UPXI?

IN8bio has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Upexi has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.

Does the MarketBeat Community prefer INAB or UPXI?

IN8bio received 22 more outperform votes than Upexi when rated by MarketBeat users. Likewise, 73.53% of users gave IN8bio an outperform vote while only 42.86% of users gave Upexi an outperform vote.

Company	Underperform	Outperform
IN8bio	Outperform Votes 25 73.53%	Underperform Votes 9 26.47%
Upexi	Outperform Votes 3 42.86%	Underperform Votes 4 57.14%

Which has better earnings and valuation, INAB or UPXI?

Upexi has higher revenue and earnings than IN8bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$30.01M	-$0.75	-0.36
Upexi	$18.63M	0.18	-$23.66M	N/A	N/A

Do insiders and institutionals have more ownership in INAB or UPXI?

92.1% of IN8bio shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 15.5% of IN8bio shares are held by insiders. Comparatively, 34.7% of Upexi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts rate INAB or UPXI?

IN8bio currently has a consensus price target of $7.75, suggesting a potential upside of 2,791.79%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe IN8bio is more favorable than Upexi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Upexi	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is INAB or UPXI more profitable?

Upexi's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-197.15%	-130.48%
Upexi	N/A	N/A	N/A

Summary

IN8bio and Upexi tied by winning 7 of the 14 factors compared between the two stocks.